Granted Patent B2

US 12,571,055 · App. 19/201,039 · Granted Mar 10, 2026

Inventors: Stefanie Ann Ward Mortimer (Morgan Hill, CA); AmirAli Talasaz (Atherton, CA); Darya Chudova (Los Altos, CA); Helmy Eltoukhy (Atherton, CA)

Assignee: Guardant Health, Inc.

C12Q1/6886C12M1/00C12M1/34C12Q1/6806C12Q1/6855C12Q1/6869G01N33/57407G16B20/20G16B30/10G16H50/20G16H50/30C12Q2600/118C12Q2600/154C12Q2600/156C12Q2600/158C12Q2600/166

Abstract

Claims (34)

1 . A method for detecting a presence or absence of residual cancer in a subject, comprising:

(a) providing a sample comprising cell-free deoxyribonucleic acid (cfDNA) molecules from a subject, wherein the sample is collected from the subject post-surgical resection of a tumor;

(b) enriching the cfDNA molecules or amplicons thereof using oligonucleotide sequence capture probes for a plurality of genes or genomic regions to generate a sequencing panel, wherein the plurality of genes or genomic regions:

(i) comprise CpG islands which are differentially methylated regions, and

(ii) are selected without using prior knowledge from the tumor;

(c) sequencing a plurality of enriched cfDNA molecules or enriched amplicons thereof to generate sequencing data; and

(d) determining methylation profiles of the cfDNA molecules from the sequencing data to detect the presence or absence of residual cancer in the subject.

2 . The method of claim 1 , wherein the sample is or is derived from a blood sample of the subject.

3 . The method of claim 1 , wherein sequencing adaptors are attached to the cfDNA molecules prior to enriching.

4 . The method of claim 3 , wherein the sequencing adaptors comprise molecular barcodes.

5 . The method of claim 1 , wherein the enriching comprises a differential tiling of the oligonucleotide sequence capture probes.

6 . The method of claim 5 , wherein the differential tiling has a depth of about 2×, 3×, 4×, 5×, 6×, 8×, 9×, 10×, 15×, 20×, 50× or more.

7 . The method of claim 1 , wherein the enriched cfDNA molecules or amplicons thereof are amplified prior to sequencing.

8 . The method of claim 1 , wherein the plurality of genomic regions comprise one or more sequences selected from the group consisting of exons, introns, promoters, 3′ untranslated regions, 5′ untranslated regions, enhancers and splice sites.

9 . The method of claim 8 , wherein a genomic region of the plurality of genomic regions comprises a transcription start site in a promoter region of a tumor suppressor gene.

10 . The method of claim 1 , wherein the sequencing panel is at least 150 kb in size.

11 . The method of claim 1 , wherein the sequencing is massively parallel sequencing that sequences at least 10 million polynucleotide molecules.

12 . The method of claim 1 , wherein the sequencing data comprises at least 1 billion, 1.1 billion, 1.2 billion, 1.5 billion, 2 billion, 2.5 billion, 3 billion, 3.5 billion, 4 billion, 4.5 billion, 5 billion, 5.5 billion, 6 billion, 6.5 billion, 7 billion, 8 billion, 9 billion or 10 billion base pairs.

13 . The method of claim 1 , wherein a read budget is selected that identifies the total number of base reads to be allocated to the sample, wherein the sample comprises a predetermined amount of DNA.

14 . The method of claim 1 , wherein the sequencing is performed at a depth of at least 50,000 reads per base, at least 100,000 reads per base, or at least 120,000 reads per base.

15 . The method of claim 14 , wherein the reads per base represent at least 5,000 original cfDNA molecules in the sample.

16 . The method of claim 1 , wherein the subject does not have a cancer that is detectable by imaging methods.

17 . The method of claim 16 , wherein the imaging method is positron emission tomography scan, magnetic resonance imaging, X-ray, computerized axial tomography scan, ultrasound, or a combination thereof.

18 . The method of claim 1 , wherein the cancer is colorectal cancer.

19 . The method of claim 18 , wherein the colorectal cancer is detected at a specificity of at least 80% or greater.

20 . The method of claim 19 , wherein the plurality of genes or genomic regions is selected for enrichment to detect the colorectal cancer at a positive predictive value (PPV) of at least 60%.

21 . The method of claim 1 , wherein sequence reads from the sequencing data are mapped to a reference sequence.

22 . The method of claim 1 , wherein the method further comprises detecting one or more genetic variants in the cfDNA molecules from the sample.

23 . The method of claim 22 , wherein the detecting one or more genetic variants in the cfDNA molecules comprises determining a consensus sequence from sequence reads obtained from the sequence data to reduce errors from amplification or sequencing.

24 . The method of claim 23 , wherein the consensus sequence is performed on a molecule-by-molecule basis or a base-by-base basis.

25 . The method of claim 23 , wherein the consensus sequence is based on assessing probabilities of each of the potential nucleotides based on observed sequence output and the sequencing and amplification error profile characteristics of an individual sample, a batch of sample, or a reference set of samples.

26 . The method of claim 23 , wherein molecular barcodes are used to group the sequencing reads into families derived from original individual cfDNA molecules, wherein the consensus sequence is generated for the family either on a molecule-by-molecule basis or a base-by-base basis.

27 . The method of claim 22 , wherein a frequency of nucleotides in the sample is determined by comparing it to a frequency of germline DNA from the subject.

28 . The method of claim 22 , wherein the genetic variants are single nucleotide variants (SNVs) and/or insertions or deletions (indels).

Assignments (1)

Continuity (18)

References Cited (198)